Feature|Articles|September 17, 2024
- Pharmaceutical Executive: September 2024
- Volume 44
- Issue 9
Pharmaceutical Executive: September 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
A Care Sea Changeover 1 year ago
Jan van de Winkel: Antibody Ascensionover 1 year ago
Biotech Performance Pivot May Be in the Offingover 1 year ago
Delivery and Disruption: Navigating a Changing Care Terrainover 1 year ago
Outsourcing’s Evolution in the Pharma Industryover 1 year ago
A Risk-Reward Reset: Getting Serious About Social Mediaover 1 year ago
Copay Adjustment Chess Match: What Will Payers Do Next?over 1 year ago
Rx Power Struggle: How Pharma can Flip the PBM ScriptNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5